Torsten Pietsch
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
Fröhlich A, Ring S, Golletz C, Pietsch T, Strieth S, Brossart P, Gielen G, Kristiansen G, Bootz F, Landsberg J, Flatz L, Hoffmann F, Sirokay J, Fietz S, Vogt T, Dietrich J, Zarbl R, Florin M, Kuster P, Saavedra G, Valladolid S, Dietrich D. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. EBioMedicine 2020; 59:102962.
Aug 30, 2020Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
Aug 30, 2020EBioMedicine 2020; 59:102962
Fröhlich Anne, Ring Sandra, Golletz Carsten, Pietsch Torsten, Strieth Sebastian, Brossart Peter, Gielen Gerrit H, Kristiansen Glen, Bootz Friedrich, Landsberg Jennifer, Flatz Lukas, Hoffmann Friederike, Sirokay Judith, Fietz Simon, Vogt Timo J, Dietrich Jörn, Zarbl Romina, Florin Mike, Kuster Pia, Saavedra Gonzalo, Valladolid Susana Ramírez, Dietrich Dimo
Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
Hoffmann F, Landsberg J, Kristiansen G, Flatz L, Pietsch T, Dietrich J, Ring S, Gielen G, Strieth S, Kuster P, Saavedra G, Brossart P, Holderried T, Posch C, Fröhlich A, Sirokay J, Niebel D, Zarbl R, Dietrich D. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clin Epigenetics 2020; 12:94.
Jun 26, 2020Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
Jun 26, 2020Clin Epigenetics 2020; 12:94
Hoffmann Friederike, Landsberg Jennifer, Kristiansen Glen, Flatz Lukas, Pietsch Torsten, Dietrich Jörn, Ring Sandra, Gielen Gerrit H, Strieth Sebastian, Kuster Pia, Saavedra Gonzalo, Brossart Peter, Holderried Tobias A W, Posch Christian, Fröhlich Anne, Sirokay Judith, Niebel Dennis, Zarbl Romina, Dietrich Dimo
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galldiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovanz M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393:678-688.
Feb 14, 2019Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Feb 14, 2019Lancet 2019; 393:678-688
Neurooncology Working Group of the German Cancer Society, Simon Matthias, Tonn Jörg-Christian, Stummer Walter, Schaub Christina, Weller Johannes, Kebir Sied, Schäfer Niklas, Stuplich Moritz, Vatter Hartmut, Misch Martin, Keil Vera C, Nelles Michael, Glas Martin, Coch Christoph, Pietsch Torsten, Hattingen Elke, Schmid Matthias, Fimmers Rolf, Weller Michael, Wick Wolfgang, Coenen Martin, Urbach Horst, Vajkoczy Peter, Galldiks Norbert, Bullinger Lars, Goldbrunner Roland, Grauer Oliver, Krex Dietmar, Kortmann Rolf-Dieter, Hau Peter, Sabel Michael, Schlegel Uwe, Steinbach Joachim Peter, Mack Frederic, Tzaridis Theophilos, Schnell Oliver, Bähr Oliver, Renovanz Miriam, Weyerbrock Astrid, Brehmer Stefanie, Suchorska Bogdana, Schmidt-Graf Friederike, Ringel Florian, Kowalski Thomas, Tabatabai Ghazaleh, Seidel Clemens, Uhl Martin, Herrlinger Ulrich
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
Beier D, Proescholdt M, Reinert C, Pietsch T, Jones D, Pfister S, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann R, Bogdahn U, Hau P. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro Oncol 2018; 20:400-410.
Feb 19, 2018Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
Feb 19, 2018Neuro Oncol 2018; 20:400-410
Beier Dagmar, Proescholdt Martin, Reinert Christiane, Pietsch Torsten, Jones David T W, Pfister Stefan M, Hattingen Elke, Seidel Clemens, Dirven Linda, Luerding Ralf, Reijneveld Jaap, Warmuth-Metz Monika, Bonsanto Matteo, Bremer Michael, Combs Stephanie E, Rieken Stefan, Herrlinger Ulrich, Kuntze Holger, Mayer-Steinacker Regine, Moskopp Dag, Schneider Thomas, Beringer Andreas, Schlegel Uwe, Stummer Walter, Welker Helmut, Weyerbrock Astrid, Paulsen Frank, Rutkowski Stefan, Weller Michael, Wick Wolfgang, Kortmann Rolf-Dieter, Bogdahn Ulrich, Hau Peter
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
Herrlinger U, Kortmann R, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Gerlach R, Vajkoczy P, Schäfer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Glas M. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 2016; 34:1611-9.
Mar 14, 2016Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
Mar 14, 2016J Clin Oncol 2016; 34:1611-9
Herrlinger Ulrich, Kortmann Rolf-Dieter, Mehdorn Maximilian, Tüttenberg Jochen, Mayer-Steinacker Regine, Fietkau Rainer, Brehmer Stefanie, Mack Frederic, Stuplich Moritz, Kebir Sied, Kohnen Ralf, Dunkl Elmar, Leutgeb Barbara, Proescholdt Martin, Pietsch Torsten, Urbach Horst, Belka Claus, Stummer Walter, Gerlach Rüdiger, Vajkoczy Peter, Schäfer Niklas, Steinbach Joachim P, Weyerbrock Astrid, Hau Peter, Goldbrunner Roland, Friedrich Franziska, Rohde Veit, Ringel Florian, Schlegel Uwe, Sabel Michael, Ronellenfitsch Michael W, Uhl Martin, Maciaczyk Jaroslaw, Grau Stefan, Schnell Oliver, Hänel Mathias, Krex Dietmar, Glas Martin
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Korfel A, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Mergenthaler H, Hundsberger T, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 2015; 84:1242-8.
Feb 25, 2015Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Feb 25, 2015Neurology 2015; 84:1242-8
Korfel Agnieszka, Junghanß Christian, Birnbaum Tobias, Fischer Lars, Jahnke Kristoph, Herrlinger Ulrich, Roth Patrick, Bamberg Michael, Pietsch Torsten, Mergenthaler Hans G, Hundsberger Thomas, Thiel Eckhard, Martus Peter, Möhle Robert, Griesinger Frank, Rauch Michael, Röth Alexander, Hertenstein Bernd, Fischer Thomas, Weller Michael
Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies
Müller K, Fleischhack G, Kortmann R, Rutkowski S, Bode U, von Bueren A, von Hoff K, Pietsch T, Warmuth-Metz M, Henke G, Budach W, Christiansen H, Zimmermann M, Siegler N, Zwiener I, Mynarek M, Tippelt S. Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies. Int J Radiat Oncol Biol Phys 2014; 88:1019-24.
Apr 1, 2014Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies
Apr 1, 2014Int J Radiat Oncol Biol Phys 2014; 88:1019-24
Müller Klaus, Fleischhack Gudrun, Kortmann Rolf-Dieter, Rutkowski Stefan, Bode Udo, von Bueren Andre, von Hoff Katja, Pietsch Torsten, Warmuth-Metz Monika, Henke Guido, Budach Wilfried, Christiansen Hans, Zimmermann Martina, Siegler Nele, Zwiener Isabella, Mynarek Martin, Tippelt Stephan
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Thiel E, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Leithäuser M, Mergenthaler H, Hundsberger T, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11:1036-47.
Oct 20, 2010High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Oct 20, 2010Lancet Oncol 2010; 11:1036-47
Thiel Eckhard, Birnbaum Tobias, Fischer Lars, Jahnke Kristoph, Herrlinger Ulrich, Plasswilm Ludwig, Nägele Thomas, Pietsch Torsten, Bamberg Michael, Leithäuser Malte, Mergenthaler Hans-Günther, Hundsberger Thomas, Korfel Agnieszka, Martus Peter, Kanz Lothar, Griesinger Frank, Rauch Michael, Röth Alexander, Hertenstein Bernd, von Toll Theda, Weller Michael